SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cambridge Antibody Technology Group
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jongmans who started this subject1/16/2004 11:35:10 AM
From: nigel bates  Read Replies (3) of 625
 
From Abbott's results PR:

Q2) How did HUMIRA perform in the fourth quarter, and what is the
outlook for 2004?

A2) The worldwide launch of HUMIRA continues to proceed well, with the
product now approved for sale in 37 countries. Worldwide HUMIRA
sales this quarter were $119 million, with full-year sales in 2003
of $280 million.

Based on the positive performance of HUMIRA in 2003, the company is
raising its 2004 worldwide sales expectations for HUMIRA to more
than $700 million.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News